Cargando…

The SLIT/ROBO Pathway in Liver Fibrosis and Cancer

Liver fibrosis is a common outcome of most chronic liver insults/injuries that can develop into an irreversible process of cirrhosis and, eventually, liver cancer. In recent years, there has been significant progress in basic and clinical research on liver cancer, leading to the identification of va...

Descripción completa

Detalles Bibliográficos
Autores principales: Basha, Sreenivasulu, Jin-Smith, Brady, Sun, Chunbao, Pi, Liya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216401/
https://www.ncbi.nlm.nih.gov/pubmed/37238655
http://dx.doi.org/10.3390/biom13050785
_version_ 1785048289349992448
author Basha, Sreenivasulu
Jin-Smith, Brady
Sun, Chunbao
Pi, Liya
author_facet Basha, Sreenivasulu
Jin-Smith, Brady
Sun, Chunbao
Pi, Liya
author_sort Basha, Sreenivasulu
collection PubMed
description Liver fibrosis is a common outcome of most chronic liver insults/injuries that can develop into an irreversible process of cirrhosis and, eventually, liver cancer. In recent years, there has been significant progress in basic and clinical research on liver cancer, leading to the identification of various signaling pathways involved in tumorigenesis and disease progression. Slit glycoprotein (SLIT)1, SLIT2, and SLIT3 are secreted members of a protein family that accelerate positional interactions between cells and their environment during development. These proteins signal through Roundabout receptor (ROBO) receptors (ROBO1, ROBO2, ROBO3, and ROBO4) to achieve their cellular effects. The SLIT and ROBO signaling pathway acts as a neural targeting factor regulating axon guidance, neuronal migration, and axonal remnants in the nervous system. Recent findings suggest that various tumor cells differ in SLIT/ROBO signaling levels and show varying degrees of expression patterns during tumor angiogenesis, cell invasion, metastasis, and infiltration. Emerging roles of the SLIT and ROBO axon-guidance molecules have been discovered in liver fibrosis and cancer development. Herein, we examined the expression patterns of SLIT and ROBO proteins in normal adult livers and two types of liver cancers: hepatocellular carcinoma and cholangiocarcinoma. This review also summarizes the potential therapeutics of this pathway for anti-fibrosis and anti-cancer drug development.
format Online
Article
Text
id pubmed-10216401
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102164012023-05-27 The SLIT/ROBO Pathway in Liver Fibrosis and Cancer Basha, Sreenivasulu Jin-Smith, Brady Sun, Chunbao Pi, Liya Biomolecules Review Liver fibrosis is a common outcome of most chronic liver insults/injuries that can develop into an irreversible process of cirrhosis and, eventually, liver cancer. In recent years, there has been significant progress in basic and clinical research on liver cancer, leading to the identification of various signaling pathways involved in tumorigenesis and disease progression. Slit glycoprotein (SLIT)1, SLIT2, and SLIT3 are secreted members of a protein family that accelerate positional interactions between cells and their environment during development. These proteins signal through Roundabout receptor (ROBO) receptors (ROBO1, ROBO2, ROBO3, and ROBO4) to achieve their cellular effects. The SLIT and ROBO signaling pathway acts as a neural targeting factor regulating axon guidance, neuronal migration, and axonal remnants in the nervous system. Recent findings suggest that various tumor cells differ in SLIT/ROBO signaling levels and show varying degrees of expression patterns during tumor angiogenesis, cell invasion, metastasis, and infiltration. Emerging roles of the SLIT and ROBO axon-guidance molecules have been discovered in liver fibrosis and cancer development. Herein, we examined the expression patterns of SLIT and ROBO proteins in normal adult livers and two types of liver cancers: hepatocellular carcinoma and cholangiocarcinoma. This review also summarizes the potential therapeutics of this pathway for anti-fibrosis and anti-cancer drug development. MDPI 2023-05-01 /pmc/articles/PMC10216401/ /pubmed/37238655 http://dx.doi.org/10.3390/biom13050785 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Basha, Sreenivasulu
Jin-Smith, Brady
Sun, Chunbao
Pi, Liya
The SLIT/ROBO Pathway in Liver Fibrosis and Cancer
title The SLIT/ROBO Pathway in Liver Fibrosis and Cancer
title_full The SLIT/ROBO Pathway in Liver Fibrosis and Cancer
title_fullStr The SLIT/ROBO Pathway in Liver Fibrosis and Cancer
title_full_unstemmed The SLIT/ROBO Pathway in Liver Fibrosis and Cancer
title_short The SLIT/ROBO Pathway in Liver Fibrosis and Cancer
title_sort slit/robo pathway in liver fibrosis and cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216401/
https://www.ncbi.nlm.nih.gov/pubmed/37238655
http://dx.doi.org/10.3390/biom13050785
work_keys_str_mv AT bashasreenivasulu theslitrobopathwayinliverfibrosisandcancer
AT jinsmithbrady theslitrobopathwayinliverfibrosisandcancer
AT sunchunbao theslitrobopathwayinliverfibrosisandcancer
AT piliya theslitrobopathwayinliverfibrosisandcancer
AT bashasreenivasulu slitrobopathwayinliverfibrosisandcancer
AT jinsmithbrady slitrobopathwayinliverfibrosisandcancer
AT sunchunbao slitrobopathwayinliverfibrosisandcancer
AT piliya slitrobopathwayinliverfibrosisandcancer